199 related articles for article (PubMed ID: 26666870)
1. Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.
Manetti F; Petricci E
Expert Opin Ther Pat; 2016; 26(4):529-35. PubMed ID: 26666870
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
[TBL] [Abstract][Full Text] [Related]
3. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
[TBL] [Abstract][Full Text] [Related]
5. Current trends in Hedgehog signaling pathway inhibition by small molecules.
Ghirga F; Mori M; Infante P
Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379
[TBL] [Abstract][Full Text] [Related]
6. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
7. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
[TBL] [Abstract][Full Text] [Related]
8. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors.
Infante P; Mori M; Alfonsi R; Ghirga F; Aiello F; Toscano S; Ingallina C; Siler M; Cucchi D; Po A; Miele E; D'Amico D; Canettieri G; De Smaele E; Ferretti E; Screpanti I; Uccello Barretta G; Botta M; Botta B; Gulino A; Di Marcotullio L
EMBO J; 2015 Jan; 34(2):200-17. PubMed ID: 25476449
[TBL] [Abstract][Full Text] [Related]
9. Targeting GLI factors to inhibit the Hedgehog pathway.
Infante P; Alfonsi R; Botta B; Mori M; Di Marcotullio L
Trends Pharmacol Sci; 2015 Aug; 36(8):547-58. PubMed ID: 26072120
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties.
Wang F; Stappenbeck F; Parhami F
Cells; 2019 May; 8(5):. PubMed ID: 31137846
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.
Wang F; Stappenbeck F; Matsui W; Parhami F
J Cell Biochem; 2017 Mar; 118(3):499-509. PubMed ID: 27490478
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
[TBL] [Abstract][Full Text] [Related]
13. The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury.
Grzelak CA; Martelotto LG; Sigglekow ND; Patkunanathan B; Ajami K; Calabro SR; Dwyer BJ; Tirnitz-Parker JE; Watkins DN; Warner FJ; Shackel NA; McCaughan GW
J Hepatol; 2014 Jan; 60(1):143-51. PubMed ID: 23978713
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling pathway inhibitors: an updated patent review (2015-present).
Quaglio D; Infante P; Di Marcotullio L; Botta B; Mori M
Expert Opin Ther Pat; 2020 Apr; 30(4):235-250. PubMed ID: 32070165
[No Abstract] [Full Text] [Related]
15. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog Inhibitors Suppress Osteoclastogenesis in In Vitro Cultures, and Deletion of
Kohara Y; Haraguchi R; Kitazawa R; Imai Y; Kitazawa S
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326611
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics.
Peukert S; Miller-Moslin K
ChemMedChem; 2010 Apr; 5(4):500-12. PubMed ID: 20229564
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Hedgehog Antagonists for Cancer Therapy.
Khatra H; Bose C; Sinha S
Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
20. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
